Skip to content

Incyte Corp

INCY· NasdaqCore metricsCIK 879169

Commercial physical & biological research16 peers

Last sale
Nov 12, 2026 · -0.44%
Market cap
$24.80B
203.83M shares
Filings
1,093
$1.56B
Q3 2026+21.2% FY25 yoy
-$784.80M
Q3 2026+3,845.0% FY25 yoy
-$708.36M
Q3 2026+2,368.6% FY25 yoy
$892.11M
FY 2022derived+56.9% FY22 yoy
-$3.86
Q3 2026+4,173.3% FY25 yoy
$3.28B
Q3 2026+83.5% FY25 yoy
$24.80B
61.5×
4.1×
4.4×
—
—

Twelve months to Sep 30, 2026 · derived

Price

$121.69+12.46%+$13.48past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$5.14BFY 2025
$5.14B0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$5,141,242,000reported
FY 20242024-12-31$4,241,217,000reported
FY 20232023-12-31$3,695,649,000reported
FY 20222022-12-31$3,394,635,000reported
FY 20212021-12-31$2,986,267,000reported
FY 20202020-12-31$2,666,702,000reported
FY 20192019-12-31$2,158,759,000reported
FY 20182018-12-31$1,881,883,000reported
FY 20172017-12-31$1,536,216,000reported
FY 20162016-12-31$1,105,719,000reported
FY 20152015-12-31$753,751,000reported
FY 20142014-12-31$511,495,000reported

Capital returns

Dividends and buybacks · FY2022 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$0.00$0.00—199.01M sh+2.8%—
FY2024—$2.00B$2.00B—193.52M sh−13.8%—
FY2023—$0.00$0.00—224.53M sh+0.7%—
FY2022—$0.00$0.00—222.97M sh+0.7%0.0%

Segments

Revenue by Geography, FY2018 to FY2025FY2018United States · FY2018 · $1.80BEurope · FY2018 · $79.90MFY2019United States · FY2019 · $2.10BEurope · FY2019 · $90.00MFY2020United States · FY2020 · $2.60BEurope · FY2020 · $105.00MFY2021United States · FY2021 · $2.90BEurope · FY2021 · $124.10MFY2022United States · FY2022 · $3.20BEurope · FY2022 · $147.00MFY2023United States · FY2023 · $3.51BEurope · FY2023 · $175.87MOther countries · FY2023 · $4.91MEurope and Japan · FY2023 · $179.30MFY2024United States · FY2024 · $3.97BEurope · FY2024 · $260.44MOther countries · FY2024 · $6.21MFY2025United States · FY2025 · $4.80BEurope · FY2025 · $323.73MOther countries · FY2025 · $17.57M
LineFY2025ShareChange
United States$4.80B93%+20.8%
Europe$323.73M6.3%+24.3%
Other countries$17.57M0.3%+182.7%
Europe and Japan———
Total$5.14B

From the 10-K filed Feb 10, 2026INCY

Commercial physical & biological research

Incyte Corp is the 3rd largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Incyte Corp · CIK 879169 · Engraved from SEC EDGAR